Best Practice & Research Clinical Obstetrics & Gynaecology
Volume 21, Issue 6 , Pages 947-967, December 2007

Second-generation endometrial ablation technologies: the hot liquid balloons

  • George A. Vilos, BSc, MD, FRCSC, FACOG, FSOGC (Professor)

      Affiliations

    • Corresponding Author InformationCorresponding author. Department of Obstetrics and Gynecology, St. Joseph's Health Care, 268 Grosvenor St., London, Ontario N6A 4VS. Tel.: +1 519 646 6104; Fax: +1 519 646 6345.
  • ,
  • Fawaz Edris, MD, RDMS, FRCSC (Clinical Fellow)

Department of Obstetrics and Gynecology, The University of Western Ontario, London, Ontario, Canada

published online 19 April 2007.

Hysteroscopic endometrial ablation (HEA) was introduced in the 1980s to treat menorrhagia. Its use required additional training, surgical expertise and specialized equipment to minimize emergent complications such as uterine perforations, thermal injuries and excessive fluid absorption. To overcome these difficulties and concerns, thermal balloon endometrial ablation (TBEA) was introduced in the 1990s.

Four hot liquid balloons have been introduced into clinical practice. All systems consist of a catheter (4-10mm diameter), a silicone balloon and a control unit. Liquids used to inflate the balloons include internally heated dextrose in water (ThermaChoice, 87°C), and externally heated glycine (Cavaterm, 78°C), saline (Menotreat, 85°) and glycerine (Thermablate, 173°C). All balloons require pressurization from 160 to 240mmHg for treatment cycles of 2 to 10 minutes.

Prior to TBEA, preoperative endometrial thinning, including suction curettage, is optional. Several RCTs and cohort studies indicate that the advantages of TBEA include portability, ease of use and short learning curve. In addition, small diameter catheters requiring minimal cervical dilatation (5-7mm) and short duration of treatment cycles (2-8min) allow treatment under minimal analgesia/anesthesia requirements in a clinic setting.

Following TBEA serious adverse events, including thermal injuries to viscera have been experienced. To minimize such injuries some surgeons advocate the use of routine post-dilatation hysteroscopy and/or ultrasonography to confirm correct intrauterine placement of the balloon prior to initiating the treatment cycle. After 10 years of clinical practice, TBEA is thought to be the preferred first-line surgical treatment of menorrhagia in appropriately selected candidates. Economic modeling also suggested that TBEA may be more cost-effective than HEA.

Key words: menorrhagia, abnormal uterine bleeding, thermal balloon endometrial ablation, ThermaChoice, Cavaterm, Menotreat, Thermablate, hot liquid balloons

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1521-6934(07)00079-X

doi:10.1016/j.bpobgyn.2007.03.022

Best Practice & Research Clinical Obstetrics & Gynaecology
Volume 21, Issue 6 , Pages 947-967, December 2007